Revelstoke recaps AOM Infusion
By HME News Staff
Updated 9:41 AM CDT, Tue April 15, 2025
DENVER – Revelstoke Capital Partners, a growth-oriented health care-focused private equity firm, has completed a recapitalization of AOM Infusion, a specialty infusion provider focused on chronic therapy management.
AOM Infusion provides patients with intravenous immunoglobulin, biologics and other therapies, addressing more than 80 different chronic conditions, with long-term treatment administered by skilled infusion nurses. The company also provides support services, including skilled infusion nursing administration, pharmacy services, referral management, insurance verification and patient education and training.
“AOM is committed to growth that enhances patient care,” said Keyur Mehta, CEO of AOM. “We are excited about the new partnership with Revelstoke, and we look forward to extending our reach by expanding our therapeutic focus areas, deepening our clinical expertise and ensuring that patients receive the highest quality infusion therapy in the most comfortable and cost-effective care settings.”
AOM is the ninth investment from Revelstoke Capital Partners Fund III.
Terms of the transaction were not disclosed.
About AOM: The company was founded in 1994 and holds pharmacy licenses in all 50 states.
About Revelstoke: The firm has about $4.8 billion of assets under management. Since its inception in 2013, it has completed 195 acquisitions, which include 30 platform companies and 165 add-on acquisitions.
Comments